FOSUN PHARMA (600196.SH) announced that its controlling subsidiary, Shanghai Henlius Biotech, Inc., along with its controlled subsidiaries (collectively referred to as "Henlius"), has received approval from the National Medical Products Administration to conduct a Phase I clinical trial for HLX97, a small molecule inhibitor targeting KAT6A/B, for the treatment of advanced or metastatic solid tumors. Henlius plans to initiate related clinical studies in China once the necessary conditions are met.